DXCM DEXCOM INC.

Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers

Dexcom, Inc. (NASDAQ: DXCM), - November is National Diabetes Awareness Month, time to bring attention to the prevalence and risk of diabetes within our diverse Canadian population, and to profile innovative strategies for prevention and management. In this context, Dexcom Canada is pleased to announce its participation in the Truckers’ Health Adaptive Technology (T.H.A.T.) project, as a digital heath technology partner, in support of improving health and safety outcomes of professional truck drivers with the introduction of real-time, data-guided virtual care and coaching.

Professional truck drivers are essential workers in our economy that and related health conditions due to the nature of their profession. In response to this challenge, Dr. Jalila Jbilou from the Université de Moncton and Centre de formation médicale du Nouveau-Brunswick, in collaboration with Routinify and Valley Healthcare Inc., developed the TH@CLINIC an innovative digital-first model of care and behavioural support for professional drivers. Dr. Jbilou, and her team, have begun to introduce this new real-world, real-time model of digital virtual care with drivers this month and, over the next year, will be assessing its impact on healthy behaviors, chronic conditions, and co-morbidities within a study population of 200 professional drivers.

The T.H.A.T. study participants’ glucose, blood pressure, heart rate, oxygen saturation, stress, sleep and physical activity data will be remotely monitored and collected daily. These health datasets, combined with waist circumference, body weight, and height will form dynamic individual biophysical and behavioral profiles, that will be used to engage drivers with real-time, targeted personalized behavioural interventions and digital virtual care supports from a multidisciplinary team of healthcare providers. Dexcom G6 real-time continuous glucose monitoring (rtCGM) systems will be used to monitor daily glucose, combined with a professional drivers’ adapted version of the Routinify’s WellAssist continuous wellness and health monitoring platform to guide drivers’ daily activities and coaching.

The T.H.A.T. project is a great example of trilateral collaboration between Government, university and industry stakeholders, including the Government of New Brunswick through (the “Labor Market Research and Analysis program”); the New Brunswick Health Research Foundation; WorkSafe NB; the Université de Moncton; trucking companies including Armour Transportation Systems, Atlantic Pacific Transport Ltd., Day & Ross, Midland Transport Ltd., Seaboard Transport and RST-Sunbury Transport, as members of the Atlantic Provinces Trucking Association; Valley Healthcare Inc.; Routinify; and Dexcom Canada.

“Professional drivers are on the road most of their time and do not have a standard work schedule. Such working conditions put them at higher risk for diabetes and other preventable chronic diseases. Moreover, only few of them are attached to a primary care professional. The TH@CLINIC offers a unique access to personalized health services, health monitoring (i.e. Dexcom CGM) and coaching to professional drivers, whenever they need support and wherever they are on the road. Findings from the T.H.A.T. project will inform the scaling up and the expansion of agile digital health to other population groups in New Brunswick and elsewhere in Canada,” says Dr. Jbilou, the principal investigator of the T.H.A.T. project.

“Dexcom Canada is pleased to support the T.H.A.T. initiative, and its vision of advanced digital virtual care to improve health and safety outcomes in the professional driver population,” says Elizabeth Whaley, Senior Director at Dexcom Canada. “We’re very excited to see our advanced real-time continuous glucose monitoring technology, and it’s connected data ecosystem, used to enable collection and reporting of glycemic data as both a comparator and component of the innovative model of care under investigation.”

With its focus on e-health literacy and remote, real-time engagement in personalized disease management, TH@CLINIC’s data-driven virtual care model could be readily applied to improve health and safety outcomes in other safety-sensitive workforces with diabetes-related risks, like transit and construction.

About Dexcom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit .

EN
30/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

Dexcom Inc: 2 directors

Two Directors at Dexcom Inc sold/bought 22,148 shares at between 55.039USD and 55.170USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

OSK OSHKOSH CORP
DXCM DEXCOM INC.
XRAY DENTSPLY SIRONA INC.
WING WINGSTOP INC.
VRTS VIRTUS INVESTMENT PARTNERS INC.
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
STKS ONE GROUP HOSPITALITY
SNPS SYNOPSYS INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SFST SOUTHERN FIRST BANCSHARES
RGNX REGENXBIO INC.
RCKY ROCKY BRANDS
PRGO PERRIGO CO. PLC
MPWR MONOLITHIC POWER SYSTEMS INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
IRM IRON MOUNTAIN INC.
GPC GENUINE PARTS COMPANY
GD GENERAL DYNAMICS CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CROX CROCS INC.
CAL CALERES INC.
BKE BUCKLE INC.
ASC ARDMORE SHIPPING
AMOT ALLIED MOTION TECHNOLOGIES
ACAD ACADIA PHARMACEUTICALS INC.
SBL SAFE BULKERS INC.
LPG DORIAN LPG
MEG. MEG ENERGY CORP.
MDU MDU RESOURCES GROUP INC
NAT NORDIC AMERICAN TANKERS LIMITED
EVTC EVERTEC INC.
FSLR FIRST SOLAR INC.
IONS IONIS PHARMACEUTICALS INC.
NMIH NMI HOLDINGS INC. CLASS A
AGYS AGILYSYS INC.
SJM J.M. SMUCKER COMPANY
FIZZ NATIONAL BEVERAGE CORP.
NHC NATIONAL HEALTHCARE CORP.
INSW INTERNATIONAL SEAWAYS INC.
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
CELH CELSIUS HOLDINGS INC.
AMD ADVANCED MICRO DEVICES INC.
TTEC TTEC HOLDINGS INC.
AVGO BROADCOM INC.
ST SENSATA TECHNOLOGIES HOLDING PLC
ELAN ELANCO ANIMAL HEALTH INC.
MEC MAYVILLE ENGINEERING
DELL DELL TECHNOLOGIES INC CLASS C
CSTM CONSTELLIUM SE CLASS A
OI O-I GLASS INC
BWMN BOWMAN CONSULTING GROUP LTD
DINO HOLLYFRONTIER CORP
EVEX EVE HOLDING INC
SPXC SPX TECHNOLOGIES INC
WEST WESTROCK COFFEE COMPANY LLC
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
AGEN AGENUS INC.
ARDT ARDENT HEALTH PARTNERS INC
PCT PROVIDENT CAP TR II SKIS 8.75%29
MKTW MARKETWISE INC
 PRESS RELEASE

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medi...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insights into access to care and perceptions of diabetes technology. During the conference, first-ever accuracy a...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch